KROS - Keros Therapeutics, Inc.
NEXT EARNINGS:
Feb 25, 2026
(in 7 days)
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$102.60
DETAILS
HIGH:
$107.00
LOW:
$96.00
MEDIAN:
$105.00
CONSENSUS:
$102.60
UPSIDE:
532.16%
Market Cap:
657.94M
Volume:
335,775
Avg Volume:
622,562
52 Week Range:
9.12-22.55
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.84
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
163
IPO Date:
2020-04-08
EPS (TTM):
-5.00
P/E Ratio:
-3.16
Revenue (TTM):
3.55M
Total Assets:
615.89M
Total Debt:
18.86M
Cash & Equiv:
559.93M
Rev Growth (5Y):
-18.7%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-31.8%
Debt/Equity:
0.03
Track Record
Statements >| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 3.55M | 151,000 | N/A | 20.10M | N/A | 10.00M | 10.00M |
| Net Income | (187.35M) | (152.99M) | (104.68M) | (58.74M) | (45.36M) | (12.34M) | (1.33M) |
| EPS | -5.00 | -5.20 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| Total Assets | 615.89M | 370.02M | 306.78M | 255.25M | 269.44M | 10.96M | 27.41M |
| Total Debt | 18.86M | 14.44M | 13.27M | 1.09M | 899,000 | 1.27M | 788,000 |
| Cash & Equivalents | 559.93M | 331.15M | 279.05M | 230.04M | 265.88M | 7.02M | 23.26M |
| Operating Cash Flow | (160.87M) | (124.51M) | (70.06M) | (62.15M) | (36.89M) | (16.00M) | 7.04M |
| Free Cash Flow | (162.80M) | (126.97M) | (71.30M) | (63.17M) | (37.19M) | (16.27M) | 6.83M |
| FCF per Share | -4.35 | -4.31 | -2.82 | -2.71 | -2.40 | -1.83 | 0.77 |
| Book Value | 571.55M | 332.21M | 277.42M | 243.17M | 261.72M | 495,000 | 12.76M |
| Cash & ST Investments | 559.93M | 331.15M | 279.05M | 230.04M | 265.88M | 7.02M | 23.26M |
| ROC Equity | -0.33 | -0.46 | -0.38 | -0.24 | -0.17 | -24.94 | -0.10 |